A61K 40/20
Cellular immunotherapy: characterised by the effect or the function of the cells
Official title: characterised by the effect or the function of the cells
A61K40/20 (Cellular immunotherapy: characterised by the effect or the function of the cells) appears on 1,767 US grants and 3,842 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,767
- Published applications
- 3,842
- Assignees
- 1,371
- Inventors
- 5,627
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 12 | 0 |
| 1998 | 11 | 0 |
| 1999 | 13 | 0 |
| 2000 | 20 | 0 |
| 2001 | 21 | 16 |
| 2002 | 40 | 97 |
| 2003 | 30 | 109 |
| 2004 | 26 | 126 |
| 2005 | 16 | 81 |
| 2006 | 40 | 117 |
| 2007 | 20 | 75 |
| 2008 | 37 | 105 |
| 2009 | 38 | 100 |
| 2010 | 61 | 137 |
| 2011 | 56 | 130 |
| 2012 | 51 | 98 |
| 2013 | 70 | 128 |
| 2014 | 74 | 137 |
| 2015 | 79 | 150 |
| 2016 | 94 | 122 |
| 2017 | 83 | 168 |
| 2018 | 96 | 185 |
| 2019 | 60 | 203 |
| 2020 | 87 | 227 |
| 2021 | 95 | 259 |
| 2022 | 97 | 289 |
| 2023 | 112 | 253 |
| 2024 | 113 | 246 |
| 2025 | 124 | 166 |
| 2026 | 81 | 118 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Microparticle-assisted Treg therapy for treatment of tissue injury and fibrosis22 Sep 2026US 12,741,026 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Methods and materials for treating cancer8 Oct 2026US 2026/0306630 A1Mayo Foundation for Medical Education and Research
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules for activating dendritic cells265US 6,429,199 B1University of Iowa Research Foundation · 2002
- High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")235US 6,040,177 AFred Hutchinson Cancer Research Center · 2000
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008
- Maturation of dendritic cells with immune response modifying compounds206US 6,558,951 B13M Innovative Properties Company · 2003
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001